EQS.PA

Unloved Quality

Equasens Société anonyme · Healthcare · France · $433M cap · $644K/day traded

EUR 26.25 -0.8% · close 20 Nov · scored 21 Nov

Unloved Quality: Strong and cheap, but the market has not warmed to it.

84
Score
Get score and insider alerts
Quality
70
Value
78
Momentum
35

As of 21 Nov 2026, the MoatMap Score for Equasens Société anonyme (EQS.PA) is 84/100, ranked against 25,000+ stocks in 38 markets (Quality 70, Value 78, Momentum 35, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
9.9x
peers 23.4x
ROE
17.2%
peers -69.7%
D/E
0.2x
peers 0.7x
Dividend %
5.3%
trailing yield

ABOUT EQUASENS SOCIÉTÉ ANONYME

Read

Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments.

FINANCIAL SUMMARY (EUR)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue193.1M214.1M219.8M—236.5M5.2%245.1M251.5M266.5M6.1%
Net margin20.3%21.7%21.4%—16.6%-3.7 pts————
EPS (EUR)2.63.13.12.42.71.2%2.72.83.39.1%
Share count15.0M15.0M15.0M—15.0M0.0%15.0M———
Balance sheet
Debt—66.5M66.0M55.8M60.9M-2.9%47.0M———
Equity165.2M196.8M227.6M—263.0M12.3%————
Debt/equity—0.3x0.3x—0.2x-0.1x————
Cash flow
Op. cash flow—57.0M57.7M47.6M59.2M1.3%48.9M———
Cash flow margin—26.6%26.3%—25.0%-1.6 pts20.0%———
Investing CF-36.2M-20.8M-42.9M—-22.5M—————
Financing CF-9.8M-35.8M-19.9M—-18.6M—————
PRICE (1Y) · EUR-9.3%
26.327.228.129.130.012 Oct2 Nov20 Nov
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 3 weeks, 3% above that low, but not back above a rising 50-day average.

SwingsAverage

Calmer than 64% of stocks we rank over the past year (volatility 35% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor (this stock): It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
EUR 26.25
RSI (14)
41.8
52-Week Range-39.7% from high
Low EUR 25.55High EUR 43.51

SCORE BREAKDOWN

Quality
70
ROIC
16.3%84.5
ROE
17.2%84.9
GP/Assets
15.8%37.0
Op. Margin
20.5%84.7
FCF/Assets
10.7%87.3
Piotroski
497.7
Int. Cover
48.2x79.0
D/E Ratio
0.18x52.1
Current Ratio
1.17x15.2
Value
78
P/E (TTM)
9.9x85.9
EV/EBITDA
8.6x72.2
P/FCF
8.2x84.7
P/B
1.6x65.2
P/S
1.6x70.6
Div Yield
5.3%89.6
Momentum
35
52W High %
60%48.7
RS 6M
-28%22.4
SMA 50/200
0.87x30.4
EPS Rev 4W
-1.1%18.6
EPS Rev 12W
—N/A
EPS Improve
+22%40.4
Q Growth
10%48.9

FUNDAMENTALS

Market Cap
$433M
P/E (Forward)
8.1x
Gross Margin
29.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EQS.PA are excluded.

TickerCompanyMkt CapScore
EQS.PAEquasens Société anonyme(you)$433M84
ALCGM.PACegedim SA$133M91
BOI.PABoiron SA$359M89
ALERS.PAEurobio Scientific Société anonyme$292M85
LNA.PALNA Santé SA$287M78
BLC.PABastide Le Confort Médical SA$153M92
VETO.PAVetoquinol SA$1.1B95
LBIRD.PALumibird SA$580M50
VIRP.PAVirbac SA$3.1B87
CLARI.PAClariane SE$1.3B55

Peer medians: ROE -69.7% · P/E 23.4x · Gross margin 69.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Equasens Société anonyme (EQS.PA): Stock Score Summary

Equasens Société anonyme (EQS.PA) has a MoatMap Score of 84/100 based on Quality (70/100), Value (78/100), and Momentum (35/100) factor scores.

Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments.

Director dealings

From 19 Feb 2026 to 20 Nov 2026, MoatMap's records hold no purchases or sales of Equasens Société anonyme (EQS.PA) shares by its directors.

EQS.PA insider filings, last 180 days

Key Financial Metrics

PriceEUR 26.25
Market Cap$433M
P/E (TTM)9.87
P/E (Forward)8.06
Price/Book1.58
Return on Equity17.2%
Return on Invested Capital16.3%
Debt/Equity0.18x
Gross Margin29.0%
Operating Margin20.5%
Revenue Growth7.4%
Dividend Yield5.3%
Free Cash Flow$53M

Equasens Société anonyme operates in the Health Information Services industry, part of the Healthcare sector (France).

Frequently Asked Questions

What is Equasens Société anonyme’s (EQS.PA) MoatMap Score?
The MoatMap Score for Equasens Société anonyme (EQS.PA) is 84/100. It is a composite of Quality (70), Value (78), and Momentum (35), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Equasens Société anonyme have an economic moat?
Equasens Société anonyme (EQS.PA) has a Quality factor score of 70/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Equasens Société anonyme in?
Equasens Société anonyme (EQS.PA) operates in the Healthcare sector, specifically the Health Information Services industry (France).